Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics (NRIX) announced key preclinical data for NX-2127, targeting B-cell malignancies, at the 62nd American Society of Hematology Annual Meeting. The company plans to initiate a Phase 1 clinical trial for relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia in H1 2021. NX-2127 is designed to overcome resistance in B-cell cancers by degrading Bruton’s tyrosine kinase (BTK) and activating T-cells, showing promising anti-tumor effects in preclinical models.
Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical firm, has announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference will take place from November 16-18, 2020, with CEO Arthur Sands presenting on November 17 at 3:20 p.m. EST. The Piper Sandler 32nd Annual Virtual Healthcare Conference will follow from December 1-3, 2020, featuring Sands on December 1. Both presentations will be available for 30 days afterward on Nurix's Events and Presentations page.
Nurix Therapeutics (NRIX) announced presentations at two significant upcoming events: the 5th Medicinal Chemistry & Protein Degradation Summit and the 62nd ASH Annual Meeting. Key highlights include data on their targeted protein degradation platform and preclinical data for NX-2127, aimed at treating B-cell malignancies. The summit presentation is by Senior Scientist Dan Robbins on November 16, focusing on new therapeutic discovery, while the ASH meeting will feature NX-2127's effects on B-cell malignancies on December 7.
Nurix Therapeutics (Nasdaq: NRIX) announced the resignation of Robert Tjian, Ph.D. from its Board of Directors, effective November 1, 2020. Dr. Tjian, who has been on the board since November 2016, will continue to support Nurix as the Chairman of its Scientific Advisory Board. His leadership is expected to guide Nurix's research on E3 ligases, a target class critical for developing therapies for cancer. The company aims to advance multiple drug candidates into clinical trials, enhancing its potential in cancer treatment.
Nurix Therapeutics Inc. (NRIX) reported its third-quarter financial results for 2020, highlighting a significant IPO that raised approximately $238.5 million in gross proceeds. Despite challenges from the COVID-19 pandemic, the company is on track for multiple IND filings, including upcoming submissions for its lead drug candidates NX-2127 and NX-1607. The net loss attributed to common stockholders was $18.5 million or ($0.59) per share, with total cash holdings reaching $395.1 million as of August 31, 2020, indicating a strong financial position to support ongoing clinical development.
Nurix Therapeutics, Inc. (NASDAQ: NRIX) will present at the 3rd Targeted Protein Degradation Summit on October 14, 2020, at 1:50 p.m. EDT. The session, titled Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels, will be led by CEO Arthur Sands, M.D., Ph.D. Nurix focuses on developing small molecule therapies to modulate cellular protein levels, aiming to treat cancer and immune disorders. Their integrated discovery platform, DELigase, identifies and advances drug candidates targeting E3 ligases.
Nurix Therapeutics announced the pricing of its initial public offering of 11,000,000 shares at $19.00 per share, aiming for gross proceeds of approximately $209 million.
The shares are set to trade on The Nasdaq Global Market under the symbol NRIX starting July 24, 2020. Additionally, underwriters have a 30-day option to buy up to 1,650,000 more shares at the IPO price. The offering is expected to close by July 28, 2020, pending customary closing conditions.